PURPOSE: To evaluate whether S-100B protein in serum is an independent prognostic marker in malignant melanoma. MATERIALS AND METHODS: S-100B protein in serum was analyzed in 1,007 consecutive patients with histologically verified cutaneous malignant melanoma. At the time of blood sampling, 876 patients were in clinical stage I, 35 were in stage II, and 96 were in stage III. The serum concentrations of S-100B protein were measured by a luminescence immunoassay (LIA). RESULTS: The mean serum concentration of S-100B protein was significantly related to clinical stage, with the lowest level in stage I and the highest in stage III. In a multivariate analysis, S-100B protein levels in serum showed the strongest prognostic impact of the factors analyzed with respect to disease-specific survival in clinical stages II to III, followed by clinical stage. Serum S-100B protein was not a significant independent prognostic factor in clinical stage I, where tumor thickness showed the strongest relation to melanoma-specific survival, followed by ulceration and satellites. CONCLUSION: This investigation contains the largest material of patients so far analyzed with the new LIA assay of S-100B protein in serum and confirms that S-100B protein in serum is correlated with clinical stage and is an independent prognostic marker in clinical stages II and III.
PURPOSE: To evaluate whether S-100B protein in serum is an independent prognostic marker in malignant melanoma. MATERIALS AND METHODS:S-100B protein in serum was analyzed in 1,007 consecutive patients with histologically verified cutaneous malignant melanoma. At the time of blood sampling, 876 patients were in clinical stage I, 35 were in stage II, and 96 were in stage III. The serum concentrations of S-100B protein were measured by a luminescence immunoassay (LIA). RESULTS: The mean serum concentration of S-100B protein was significantly related to clinical stage, with the lowest level in stage I and the highest in stage III. In a multivariate analysis, S-100B protein levels in serum showed the strongest prognostic impact of the factors analyzed with respect to disease-specific survival in clinical stages II to III, followed by clinical stage. Serum S-100B protein was not a significant independent prognostic factor in clinical stage I, where tumor thickness showed the strongest relation to melanoma-specific survival, followed by ulceration and satellites. CONCLUSION: This investigation contains the largest material of patients so far analyzed with the new LIA assay of S-100B protein in serum and confirms that S-100B protein in serum is correlated with clinical stage and is an independent prognostic marker in clinical stages II and III.
Authors: Elisabeth Paus; Mads Haugland Haugen; Kari Hauge Olsen; Kjersti Flatmark; Gunhild Mari Maelandsmo; Olle Nilsson; Eva Röijer; Maria Lundin; Christian Fermér; Maria Samsonova; Yuri Lebedin; Torgny Stigbrand Journal: Tumour Biol Date: 2010-07-24
Authors: Emanuelle M Rizk; Angelina M Seffens; Megan H Trager; Michael R Moore; Larisa J Geskin; Robyn D Gartrell-Corrado; Winston Wong; Yvonne M Saenger Journal: Am J Clin Dermatol Date: 2020-02 Impact factor: 7.403
Authors: Klaus Strobel; Jeannine Skalsky; Victor Kalff; Katrin Baumann; Burkhardt Seifert; Helen Joller-Jemelka; Reinhard Dummer; Hans C Steinert Journal: Eur J Nucl Med Mol Imaging Date: 2007-03-28 Impact factor: 9.236
Authors: Teodóra Bánfalvi; Mariann Boldizsár; Maria Gergye; Katalin Gilde; Tibor Kremmer; Szabolcs Ottó Journal: Pathol Oncol Res Date: 2003-01-06 Impact factor: 3.201
Authors: S Kruijff; E Bastiaannet; A C Muller Kobold; R J van Ginkel; A J H Suurmeijer; H J Hoekstra Journal: Ann Surg Oncol Date: 2009-12 Impact factor: 5.344